deCODE Isolates Two Major New Obesity Genes under Alliance with Merck

Dec 11, 2003 | NEWS

Common forms of these genes confer significant predisposition to obesity Reykjavik, ICELAND, December 11, 2003 — deCODE genetics (Nasdaq:DCGN) today announced that it has isolated two new genes as part of its alliance with Merck & Co, Inc. to develop drugs for...

deCODE Licenses Developmental Compound, Expects to Start Enrollment for Phase II Clinical Trial in Myocardial Infarction at the Beginning of Next Year

Nov 19, 2003 | NEWS

Reykjavik, ICELAND, November 17, 2003 — deCODE genetics (Nasdaq:DCGN) today announced that it has acquired an exclusive worldwide license from Bayer AG to develop and commercialize a small molecule compound. The compound is active against a key target, located within...

deCODE and Roche Diagnostics Announce Discovery of Significant Genetic Risk Factors for Heart Attack DNA-based diagnostics applying these findings may enable more targeted, individualized prevention strategies

Oct 17, 2003 | NEWS

Reykjavik, ICELAND, and Basel, SWITZERLAND, October 17, 2003 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) and Roche Diagnostics today announced a landmark discovery under their alliance to develop DNA-based diagnostic tests for common diseases. deCODE scientists have...

deCODE Announces Milestone in its Obesity Alliance with Merck

Sep 30, 2003 | NEWS

deCODE has discovered a gene with certain variations that predispose to obesity and others that predispose to thinness Reykjavik, ICELAND, September 30, 2003 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) today announced that it has achieved a milestone under its...

deCODE Study Identifying the First Gene Ever Linked to Common Forms of Stroke Published in Nature Genetics

Sep 23, 2003 | NEWS

September 23, 2003 deCODE has identified both at-risk and pretective haplotypes within the PDE4D gene, and is applying its findings to develop novel drugs and diagnostics deCODE’s landmark study in the genetics of stroke, identifying the first gene ever linked to...

deCODE’s RoboHTC™ System to Support AstraZeneca’s Structure-based Drug Design Capabilities

Apr 8, 2003 | NEWS

RoboHTC is an integrated hardware and informatics solution for designing, generating, imaging, storing and annotating protein crystallization experiments Reykjavik, ICELAND, April 8, 2003 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) today announced that AstraZeneca...